| Field | Specification |
|---|---|
| Target | |
| Alternative names | SC1 |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C27H25F3N8O2 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Pluripotin, also known as SC1, is a dual inhibitor of ERK1 and RasGAP, with Kd values of 98 nM and 212 nM, respectively. It also inhibits RSK1, RSK2, RSK3 and RSK4, with IC50 values of 0.5 μM, 2.5 μM, 3.3 μM and 10.0 μM, respectively. It is supplied as a white to off-white solid (C27H25F3N8O2, MW 550.54) at 98.86% purity.
Physical & Chemical Properties
| CAS Number | 839707-37-8 |
|---|---|
| Molecular Formula | C27H25F3N8O2 |
| Molecular Weight | 550.54 g/mol |
| Purity | 98.86% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | CN1C(NC2=NC=C3C(N(C)C(N(C4=CC(NC(C5=CC=CC(C(F)(F)F)=C5)=O)=CC=C4C)C3)=O)=N2)=CC(C)=N1 |
| Target | ERK1, RasGAP, RSK1, RSK2, RSK3, RSK4 |
| Signaling Pathway | MAPK/ERK Pathway; Stem Cell/Wnt |
| Solubility | In Vitro: DMSO: 25 mg/mL (45.41 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 2 years; -20°C, 1 year. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target
[1][2]
|
ERK1 98 nM (Kd) |
RasGAP 212 nM (Kd) |
RSK1 0.5 μM (IC50) |
RSK2 2.5 μM (IC50) |
RSK3 3.3 μM (IC50) |
RSK4 10 μM (IC50) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 25 mg/mL (45.41 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 2 years) or -20°C (up to 1 year); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.5 mg/mL (4.54 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.5 mg/mL (4.54 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
Pluripotin (SC-1) inhibits Abl1 (IC50 0.005 μM), p70S6K (1.4 μM), PLK2 (2.2 μM), RSK1 (0.5 μM), RSK2 (2.5 μM), RSK3 (3.3 μM) and RSK4 (10.0 μM). Pluripotin (SC-1) reduces the growth of 7 colon tumor cell lines. After five days of exposure to 0.1 μM SC-1, the seven colon tumor lines are assessed for changes in cell number and viability, and show a statistically significant decrease in cell number while viability remains >95%[2].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Cell Assay[2]
Use seven colon cancer lines: COLO 205, HCC-2998, HCT-15, HCT-116, HT29, KM12, SW-620. In all experiments, culture each tumor line in 60 mm2 tissue culture-treated dishes at an initial concentration of 62,500/mL (total 4 mL), and the next day add 0.1 μM Pluripotin (SC-1) or an equivalent amount of diluent (DMSO). Run five-day exposures. Determine the final treatment concentration for all tumor lines by testing SC-1 concentrations from 0.01 to 10 μM in the HCT-116 tumor line for sphere formation and any cytotoxic effects. Evaluate cell viability routinely by trypan blue exclusion test; viability is always >95% at concentrations at or below 0.1 μM[2].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
